Isohelix Files US FDA Pre-Submission for GeneFix Saliva DNA Collectors
11 January 2023 | Wednesday | News
Isohelix (UK), the specialist biological sample collection company, announces that it has commenced engagement with the U.S. Food and Drug Administration ("FDA") to progress the full regulatory approval of the GeneFix® Saliva DNA Collectors into the USA.
Image Source : Public Domain
The GeneFix® Saliva DNA/RNA Collection devices are market leading and designed for the collection and preservation of DNA/RNA from saliva, providing patients with the opportunity to provide high-quality samples for molecular diagnostics at both point of care settings and for over the counter direct to consumer genetic testing (OTC).
Isohelix has submitted via the FDA’s Pre-Submission process ("Pre-Sub"), which allows the company to clarify its testing and validation approach, confirm the appropriate regulatory application pathway (510k) and gain additional procedural feedback from the FDA with the aim of making the final submission process more efficient.
Since 2013, Isohelix has been successfully supplying its range of high-quality DNA and RNA saliva collectors and isolation products to the Diagnostics, Clinical and Research markets, with many products already certified for use as IVD’s across the globe. Isohelix is an international business marketing its sizeable product range through customers in many countries worldwide.
Tom Hole, CEO of Isohelix, said: "The US is a particularly attractive territory and the 510 (K) would allow us to supply our products into the rapidly expanding areas of Molecular and Precision Genetic Diagnosis and Testing, where saliva has become a strong choice as an alternative to blood or the use of buccal swabs. Isohelix provides saliva collectors that are proven to cope with the most demanding downstream processes, yet are easy to use for automated applications, non-hazardous and reliably stabilize both DNA and RNA over extended periods at room temperature.
Isohelix has submitted via the FDA’s Pre-Submission process ("Pre-Sub"), which allows the company to clarify its testing and validation approach, confirm the appropriate regulatory application pathway (510k) and gain additional procedural feedback from the FDA with the aim of making the final submission process more efficient.
Since 2013, Isohelix has been successfully supplying its range of high-quality DNA and RNA saliva collectors and isolation products to the Diagnostics, Clinical and Research markets, with many products already certified for use as IVD’s across the globe. Isohelix is an international business marketing its sizeable product range through customers in many countries worldwide.
Tom Hole, CEO of Isohelix, said: "The US is a particularly attractive territory and the 510 (K) would allow us to supply our products into the rapidly expanding areas of Molecular and Precision Genetic Diagnosis and Testing, where saliva has become a strong choice as an alternative to blood or the use of buccal swabs. Isohelix provides saliva collectors that are proven to cope with the most demanding downstream processes, yet are easy to use for automated applications, non-hazardous and reliably stabilize both DNA and RNA over extended periods at room temperature.
Most Read
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
